Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 7/20 | 0.42 |
| ▸ | TMPRSS6 | Q8IU80 | 7/20 | 0.42 |
| ▸ | PLAU | P00749 | 8/20 | 0.41 |
| ▸ | PLG | P00747 | 4/20 | 0.41 |
| ▸ | PLAT | P00750 | 2/20 | 0.40 |
| ▸ | MMP7 | P09237 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6432939 | 0.90 | F2 (0.47) | F2TMPRSS6PLAUPLGPLAT | |
| SCHEMBL6433471 | 0.87 | PLAU (0.40) | PLAUPLGPLATMMP7MMP2 | |
| SCHEMBL6432712 | 0.87 | PLAU (0.46) | PLAUPLGPLATCTSLCTSS | |
| SCHEMBL6434317 | 0.84 | PLAU (0.51) | PLAUPLGPLAT | |
| SCHEMBL6437934 | 0.84 | PLAU (0.53) | PLAUPLGPLAT | |
| Trifluoroacetic Acid SCHEMBL6433466 | 0.80 | MMP9 (0.46) | PLAUPLGPLATMMP7MMP2 | |
| SCHEMBL6434734 | 0.79 | PLAU (0.49) | F2TMPRSS6PLAUPLGPLAT | |
| Trifluoroacetic Acid SCHEMBL6434310 | 0.78 | PLAU (0.63) | PLAUPLGPLAT | |
| SCHEMBL6435148 | 0.78 | PLAU (0.55) | PLAUPLGCTSLCTSS | |
| SCHEMBL6438581 | 0.78 | PLAU (0.51) | F2TMPRSS6PLAUPLGPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1077945-B1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER (US) | 2003-01-08 | — | — | EP | disclosed |
| US-6093731-A | Isoquinolines | PFIZER INC. | 2000-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199440-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | F2 350/4885TMPRSS6 543/4885PLAU 119/4885 |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | F2 350/4885TMPRSS6 543/4885PLAU 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.